3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Pancreatic Neoplasms
10
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Melanoma
4
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Colonic Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Localized Prostate Cancer
1
Refractory or Relapsed Solid Tumors
1
Interventions
Imatinib Mesylate
2
midostaurin
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Watchful Waiting
1
Transplantation
1
Tacrolimus
1
Single-Cell Gene Expression Analysis
1
Radiotherapy
1
Phlebotomy
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Injections
1
Hydroxychloroquine
1
Dasatinib
1
Cyclophosphamide
1
Cladribine
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mastocytosis
×
Hydroxychloroquine
×
Clear all
NCT05084872
2021-10-20
HCQMa
University Hospital, Toulouse
Phase 2/3
Unknown
30 enrolled